The story begins with an untargeted look at metabolism. Using liquid chromatography–mass spectrometry, the researchers compared urea cycle metabolites in Philadelphia chromosome-positive B-ALL cells, which carry the t(9;22) translocation that fuses BCR to ABL, with metabolites in healthy human B cells freshly isolated from peripheral blood. The leukaemia cells stood out for elevated levels of ASA and altered handling of citrulline and arginine, the substrates and products that bracket the ASA step of the cycle. Urea cycle gene expression profiles in patient-derived cells and in the Sup-B15 and Nalm21 B-ALL lines reinforced the picture that this pathway, generally associated with the liver’s ammonia detoxification, was being co-opted in malignant B cells.

Why would BCR–ABL care about a urea cycle enzyme? The answer the authors provide is a phosphorylation event. Through mass spectrometric mapping of tyrosine-phosphorylated proteins, they identified argininosuccinate synthase 1 (ASS1), the enzyme that condenses citrulline and aspartate into ASA, as a direct substrate of the BCR–ABL kinase. Four high-confidence tyrosine residues were detected, and mutation analysis pinpointed tyrosine 282 (Y282) as the functionally important site. In vitro, purified GST-tagged Abl kinase phosphorylated wild-type ASS1 but not an ASS1-Y282F mutant, and in cells the interaction was verified by co-immunoprecipitation in both directions. Treatment with the kinase inhibitor STI571, better known as imatinib, reduced ASS1 phosphorylation, tying the modification directly to BCR–ABL activity.

Notably, Y282 phosphorylation was not a quirk of BCR–ABL alone. When the team co-expressed ASS1 with other fusion tyrosine kinases implicated in haematological malignancies, including ALK, JAK2, FGFR and PDGFR, ASS1 phosphorylation and enzymatic activity rose in each case, and kinase inhibitors lowered urea cycle metabolite levels in a chronic myelogenous leukaemia line and in anaplastic large cell lymphoma cells. This suggests that ASS1 phosphorylation at Y282 is a convergent metabolic endpoint of oncogenic tyrosine kinase signalling, one that boosts the enzyme’s capacity to convert citrulline into ASA.

What does the extra ASA actually do? The key experiments traced the fate of isotopically labelled citrulline in leukaemia cells. When B-ALL cells were fed [13C5]citrulline, labelled carbon flowed through ASA into arginine, confirming active flux through ASS1. Cells expressing a phosphorylation-deficient ASS1-Y282F mutant accumulated less ASA and arginine than cells with the wild-type enzyme. The team then depleted ASS1 with short hairpin RNAs and performed metabolomic profiling of BCR–ABL-positive BAF3 cells recovered from mouse bloodstreams. The most striking changes appeared in purine metabolism: nucleotides and nucleosides dropped when ASS1 was silenced, implicating the urea cycle intermediate in maintaining purine pools.

The mechanistic link turned out to be a direct protein–metabolite interaction. ASA, the authors show, binds cytosolic 5′-nucleotidase II (NT5C2), an enzyme that removes phosphate groups from nucleoside monophosphates to yield nucleosides such as inosine, adenosine and guanosine. Molecular docking and molecular dynamics simulations, performed by Mingjie Liu and Xiaojing He’s groups, indicated that ASA localizes to the effector site of NT5C2 and stabilizes helix A, a structural element (residues Gly355–Glu364) that gates the enzyme’s allosterically activated state. Enzyme kinetics assays confirmed that ASA enhances NT5C2’s nucleotidase activity, whereas arginine and adenylosuccinate did not reproduce the effect. In other words, ASA is not merely a passive intermediate here; it is a small-molecule activator that tells NT5C2 to convert purine nucleotides into nucleosides.

Those nucleosides, it turns out, are not waste products but fuel. When leukaemia cells were incubated with [ribose-13C5]inosine or [ribose-13C5]adenosine, label from the ribose moiety appeared in glycolytic intermediates, tricarboxylic acid (TCA) cycle metabolites and the pentose phosphate pathway, even when glucose was abundant. The purine nucleosides serve as a carbon source for central carbon metabolism under glucose-replete conditions, an unexpected contribution given that nucleoside salvage is usually framed in terms of nitrogenous bases and nucleotide pools rather than carbon economics. Earlier work had shown that ribose salvaged from uridine can fuel glucose-restricted pancreatic cancer; this study extends the concept to purine nucleosides in glucose-rich leukaemia, where they complement rather than replace glycolysis.

The physiological importance of the axis became clear in vivo. Loss of ASS1 or NT5C2 disrupted central carbon metabolism and inhibited leukaemia progression in mouse models, and supplementing the animals’ leukaemia cells with inosine or adenosine rescued the metabolic and growth defects. In Nalm21-based xenografts, an ASS1-Y282F mutant supported less disease burden than wild-type ASS1, and inosine administration partially restored phenotypes suppressed by imatinib, consistent with the nucleosides acting downstream of the kinase. Serum measurements in leukaemia-bearing mice showed elevated adenosine, inosine and cytidine compared with healthy controls, hinting that the pathway shapes the systemic nucleoside environment as well as the intracellular one.

The study also maps the transport machinery that moves these metabolites across the membrane. Uptake experiments with doubly labelled [13C6,15N4]ASA identified SLC13A2 and SLC13A3 as candidate ASA transporters, while citrulline import depended on SLC7A5, the amino acid transporter also known as LAT1, and was blocked by the LAT1 inhibitor JPH203. These assignments sharpen the metabolic wiring diagram and point to additional potential intervention points.

The findings carry a double significance for leukaemia biology and therapy. First, they identify an ASA–NT5C2 signalling axis that directly links tyrosine kinase activity, urea cycle dysregulation and purine metabolism, adding a concrete molecular mechanism to the growing appreciation of metabolites as signalling molecules. Second, they highlight purine nucleosides as a carbon source that tyrosine kinase-driven leukaemias exploit, and NT5C2 as an enzymatic node essential to that exploitation. NT5C2 is already notorious in the clinic because acquired mutations in relapsed lymphoblastic leukaemia confer resistance to thiopurine chemotherapy by altering the enzyme; this work now gives the protein a second, more fundamental role in leukaemia metabolism that is independent of treatment selection. Whether targeting the ASS1–NT5C2 axis can be translated into combination strategies with existing kinase inhibitors will require further preclinical and clinical evaluation, but the study establishes a clear metabolic vulnerability: cut off the urea cycle’s signalling output, and the leukaemia cell’s carbon supply begins to starve.

Subject of Research: The role of ASS1-derived argininosuccinate in promoting purine nucleoside synthesis and central carbon metabolism in B cell acute lymphoblastic leukaemia.

Article Title: ASS1-derived argininosuccinate promotes purine nucleoside synthesis in B cell acute lymphoblastic leukaemia

Article References: Li, G., He, Z., Liu, M., Zhao, J., Zhu, H., Zhou, C., Wang, Z., He, X., Tang, J., & Jiang, P. (2026). ASS1-derived argininosuccinate promotes purine nucleoside synthesis in B cell acute lymphoblastic leukaemia. Nature Metabolism, 8(9), 1871-1887. https://doi.org/10.1038/s42255-026-01586-w

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01586-w

Keywords: ASS1, argininosuccinate, NT5C2, BCR-ABL, B-ALL, urea cycle, purine metabolism, cancer metabolism, leukaemia, tyrosine kinase, nucleosides, Nature Metabolism

The research team focused on canavanine, a naturally occurring structural analogue of L-arginine found in certain legumes such as jack bean. Because canavanine closely resembles arginine in shape and charge, cells can mistakenly incorporate it into proteins in place of arginine, a process that produces malformed, dysfunctional proteins and ultimately cytotoxicity. This property has long made canavanine an object of interest in cancer research, but its precise effects on the regulatory circuitry of arginine metabolism had remained incompletely understood. The new work demonstrates that canavanine does far more than simply poison protein synthesis; it actively participates in the cellular signaling networks that govern how tumor cells sense and respond to arginine availability.

Central to the study is argininosuccinate synthetase 1, or ASS1, an enzyme of the urea cycle that catalyzes the rate-limiting step in the conversion of citrulline and aspartate into argininosuccinate, a precursor of arginine. ASS1 expression is a key determinant of whether a cancer cell can survive arginine deprivation therapy. Tumors with low or silenced ASS1 cannot make their own arginine and are therefore vulnerable to enzymes such as recombinant human arginase 1 or arginine deiminase, which deplete circulating arginine. Conversely, tumors that retain robust ASS1 expression can adapt to arginine starvation by synthesizing the amino acid from citrulline, rendering deprivation therapy ineffective. Understanding what controls ASS1 expression under conditions of arginine stress is therefore of substantial clinical relevance.

Using colorectal carcinoma cell lines cultivated in both complete medium and arginine-free medium, the investigators systematically examined how canavanine affects cellular signaling and gene regulation. Their most striking finding was that canavanine represses transcription of the ASS1 gene in colorectal carcinoma cells subjected to arginine starvation. In other words, the plant mimic does not merely stand in for arginine in protein synthesis; it also mimics arginine’s role in the regulatory pathways that shut down arginine biosynthesis when the cell senses sufficient arginine supply. This feedback-like behavior, now triggered by a drug-like compound, could deepen the metabolic deficit that arginine deprivation therapy is designed to create.

Intriguingly, the researchers established that this repression of ASS1 occurs in a c-Myc-independent manner. The transcription factor c-Myc has been implicated in the regulation of metabolic genes, including components of the urea cycle, in several cancer contexts, and one might have expected its involvement here. The finding that canavanine-mediated ASS1 silencing proceeds without c-Myc suggests that alternative regulatory mechanisms, possibly involving other transcriptional repressors or epigenetic modifications, are at play. This distinction matters because it points to previously unappreciated control points in the arginine metabolic network that could be targeted pharmacologically to sensitize tumors to deprivation therapy.

Beyond gene regulation, the study documented that canavanine dysregulates broader cellular signaling pathways in the stressed colorectal carcinoma cells. The authors observed effects consistent with the compound mimicking arginine in several regulatory routes, echoing behaviors previously described for other arginine analogues such as indospicine, thioarginine, and homoarginine, which the team considered in framing their experimental design. Analogues of amino acids have historically served as powerful probes of cellular metabolism precisely because they infiltrate the same transport, biosynthetic, and regulatory systems as their natural counterparts. By mapping which signaling nodes respond to canavanine under arginine starvation, the study provides a molecular picture of how tumor cell physiology unravels when arginine homeostasis is doubly compromised, first by external deprivation and then by internal mimicry.

Perhaps the most therapeutically consequential observation is that pre-exposure to arginine deprivation additionally sensitizes colorectal carcinoma cells to the cytotoxic effects of canavanine. Cells that were first grown in arginine-free conditions became more vulnerable to subsequent canavanine treatment than cells maintained in complete medium. This sequencing effect suggests that arginine starvation primes tumor cells, weakening their metabolic flexibility and protein synthesis machinery, so that the counterfeit amino acid inflicts maximal damage once it is introduced. Clinically, this raises the possibility of rational combination and sequential regimens in which an arginine-degrading enzyme is administered first, followed by canavanine, to achieve a two-step metabolic assault that tumor cells cannot easily withstand.

The findings may help resolve two persistent shortcomings of arginine deprivation therapy. The first is resistance: tumors that maintain ASS1 expression can escape starvation by producing arginine from citrulline, and some tumors upregulate ASS1 adaptively under treatment pressure. A compound that actively represses ASS1 transcription, as canavanine does under arginine-free conditions, could counteract this adaptive route and keep the metabolic door closed. The second shortcoming is incomplete efficacy as a monotherapy, which has motivated the search for combinations. The demonstration that deprivation pre-exposure potentiates canavanine cytotoxicity offers an evidence-based rationale for scheduling these agents together, a strategy that could extend to cancers beyond colorectal carcinoma, including entities such as melanoma and hepatocellular carcinoma that have been evaluated for arginine dependency.

The work also carries broader scientific significance for the field of cancer metabolism. It illustrates that a single metabolite analogue can simultaneously act at multiple levels, substituting for arginine during translation, perturbing signal transduction, and reshaping the transcriptional landscape of metabolic genes. This pleiotropy underscores the dense interconnection between nutrient sensing, protein homeostasis, and gene expression in tumor cells. Moreover, because ASS1 silencing in many tumors occurs through epigenetic mechanisms such as promoter methylation, the observation that canavanine can drive ASS1 downregulation in a c-Myc-independent way invites further investigation into whether amino acid availability itself, and arginine mimics in particular, can shape the epigenetic state of metabolic genes during therapy.

The study, conducted by G. Y. Shuvayeva, Y. P. Bobak, O. I. Chen, O. I. Vovk, and O. V. Stasyk, is available as an open access article, allowing clinicians, cancer biologists, and metabolic researchers worldwide to examine the data in full. While the experiments were performed in vitro and will require validation in preclinical models before any translational application, they provide a compelling mechanistic foundation for combining arginine deprivation with canavanine in metabolic therapeutic modalities for colorectal carcinoma and potentially other ASS1-deficient cancers. As arginine deprivation therapy continues to be evaluated across a number of tumor entities, this work adds a molecularly grounded rationale for the next generation of combination strategies aimed at starving tumors of the amino acids they can no longer live without.

Subject of Research: Effects of canavanine on cellular signaling and ASS1 expression in colorectal carcinoma cells under arginine deprivation

Article Title: Canavanine dysregulates cellular signaling and represses ASS1 under arginine deprivation in colorectal carcinoma cells

Article References: Shuvayeva, G. Y., Bobak, Y. P., Chen, O. I., Vovk, O. I., & Stasyk, O. V. (2026). Canavanine dysregulates cellular signaling and represses ASS1 under arginine deprivation in colorectal carcinoma cells. Cancer Cell International. https://doi.org/10.1186/s12935-026-04450-9

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04450-9

Keywords: arginine deprivation therapy, canavanine, ASS1, colorectal carcinoma, cancer metabolism, argininosuccinate synthetase, urea cycle, c-Myc, chemotherapy, amino acid analogue, cancer therapy, metabolic treatment

The significance of the work lies in how it reframes a familiar metabolic enzyme. ASS1 catalyses the condensation of citrulline and aspartate to form argininosuccinate, a step classically assigned to the urea cycle, the pathway by which cells dispose of excess nitrogen. For decades, cancer biologists viewed urea cycle enzymes mainly through the lens of nitrogen handling and arginine auxotrophy, with some tumours silencing ASS1 and becoming dependent on external arginine. The new study overturns that simplistic picture for B-ALL. Far from being silenced, ASS1 in these leukaemic cells is highly active and, crucially, heavily phosphorylated. The researchers detected elevated ASS1 phosphorylation both in samples from patients with B cell acute lymphoblastic leukaemia and in leukaemic cells grown in the laboratory, suggesting that the modification is a consistent feature of the disease rather than a laboratory artefact.

Phosphorylation, the attachment of a phosphate group to a protein, is one of the cell’s most common ways of changing an enzyme’s behaviour, and in this case the modification appears to redirect ASS1’s product towards an entirely new fate. Rather than flowing onward through the urea cycle, the argininosuccinate generated by phosphorylated ASS1 accumulates and acts as a signalling molecule. The team showed that this ASS1-derived argininosuccinate binds to and activates NT5C2, a cytosolic 5′-nucleotidase whose name will be familiar to leukaemia researchers for less benign reasons: mutations in the NT5C2 gene are a well-known driver of relapse in acute lymphoblastic leukaemia because they confer resistance to thiopurine chemotherapy. The new work reveals a wild-type function of the enzyme that may explain why leukaemic cells depend on it in the first place.

Once activated by argininosuccinate, NT5C2 promotes purine nucleoside biosynthesis. Purines are the building blocks of DNA and RNA, and a leukaemic cell committed to division must synthesize them in enormous quantities. But purine metabolism contributes more than genetic raw material. The flux through nucleotide synthesis pathways also generates and consumes central carbon metabolites, linking nucleoside production to the broader carbon economy of the cell. By stimulating this pathway, the argininosuccinate–NT5C2 axis effectively replenishes cellular carbon sources that would otherwise be depleted by the relentless biosynthetic demands of fast-growing cells. In essence, a urea cycle intermediate has been conscripted as a signal that tells the nucleotide machinery to ramp up production, sustaining both the material and the energetic foundations of the cancer cell.

This kind of metabolic rewiring is a hallmark of cancer, and the study adds a sophisticated twist to the growing catalogue of how tumours exploit metabolism. Cancer cells routinely divert metabolites from their canonical routes into support functions for growth and survival. What makes the B-ALL mechanism striking is the dual role of argininosuccinate as both a metabolic intermediate and an allosteric activator of an enzyme in a different pathway. The finding illustrates how metabolites can function as signalling molecules in their own right, a concept that has gained traction as researchers uncover metabolite-dependent regulation of enzymes far beyond the pathways in which those metabolites were first characterized. In B-ALL, the signalling metabolite is produced by an enzyme whose expression and modification state determine whether the entire carbon-replenishment program can run.

The clinical context sharpens the importance of the discovery. B cell acute lymphoblastic leukaemia is the most common childhood cancer, and while cure rates have improved dramatically, subgroups of patients fare poorly. Among the most challenging are cases driven by oncogenic tyrosine kinases, most famously the BCR–ABL fusion protein that defines Philadelphia chromosome-positive disease. Tyrosine kinase inhibitors such as imatinib transformed the outlook for many patients, yet resistance and relapse remain persistent problems, and the metabolic adaptations that allow leukaemic cells to survive targeted therapy are incompletely understood. The new study suggests that ASS1 phosphorylation and the downstream argininosuccinate–NT5C2 circuit constitute one such adaptation, a metabolic lifeline that supports proliferation independently of the oncogenic kinase itself. That independence matters therapeutically, because it offers a point of attack that could complement rather than duplicate existing drugs.

The authors argue that both ASS1 and NT5C2 are potential therapeutic targets for tyrosine kinase-driven haematological malignancies. Inhibiting ASS1 would starve the cells of argininosuccinate and shut down the aberrant signal at its source, while blocking NT5C2 would sever the connection between the signal and purine nucleoside production. Either strategy, in principle, would deprive leukaemic cells of the carbon replenishment they need to sustain rapid division. The involvement of NT5C2 is especially tantalizing because pharmacological inhibitors of the enzyme already attract interest, and its established role in chemoresistance means that inhibiting it could deliver a double blow, undermining both the metabolic support program and a known mechanism of treatment failure. ASS1 inhibition is less straightforward, since the enzyme also performs essential functions in normal arginine and nitrogen metabolism, and any therapeutic strategy would need to navigate the tissue-specific consequences of blocking a urea cycle enzyme.

The broader literature on ASS1 in cancer underscores how context-dependent its behaviour is. Studies spanning diverse tumour types have shown heterogeneous expression patterns of the enzyme, with some cancers losing ASS1 and becoming arginine-dependent, a vulnerability exploited by arginine-degrading therapies, while others maintain or even increase ASS1 expression to support growth. Recent work in T cell acute lymphoblastic leukaemia reported that ASS1 facilitates disease progression through arginine-mediated mTORC1 and c-Myc signalling, and that the enzyme is expressed in Philadelphia chromosome-positive ALL but not in other ALL subtypes. Meanwhile, a 2026 preprint reported that a subset of patient samples with Philadelphia chromosome-positive B-ALL shows low ASS1 expression, hinting that not every case of the disease will share the vulnerability identified in the Nature Metabolism study. These observations caution that ASS1 status may serve as a biomarker that stratifies patients, with ASS1-high tumours being the ones most likely to respond to strategies targeting the argininosuccinate–NT5C2 axis.

From a basic science perspective, the study also prompts new questions about how ASS1 phosphorylation is regulated in B-ALL. Kinases downstream of oncogenic signalling pathways are the obvious candidates, and dissecting which kinase places the phosphate on ASS1, and whether that modification tracks with disease stage or treatment response, will be a natural next step. It will also be important to map precisely how NT5C2 activation translates into enhanced purine nucleoside biosynthesis, since the enzyme’s canonical activity is the dephosphorylation of nucleoside monophosphates, and its contribution to net nucleoside synthesis may involve additional layers of metabolic coordination. Understanding these details could reveal further vulnerabilities, for example points where the argininosuccinate signal could be mimicked or blocked by small molecules.

For patients, the road from mechanism to medicine is long, but the study offers a concrete and testable proposition: that a leukaemic cell’s carbon supply can be cut off by attacking a urea cycle enzyme and the nucleotidase it controls. Given the pressing need for new approaches in relapsed and refractory B-ALL, particularly in tyrosine kinase-driven disease where the leukaemia eventually outmanoeuvres targeted inhibitors, a metabolic strategy that targets the cell’s underlying supply lines has evident appeal. The work also adds to a shift in how the field thinks about metabolism in cancer, away from a static catalogue of altered pathway activities and towards a dynamic view in which metabolites act as signals that reorganize cellular programs on demand. In B cell acute lymphoblastic leukaemia, that signal is argininosuccinate, the messenger is NT5C2, and the prize is the continuous carbon flow that keeps the cancer growing. Interfering with that conversation, the researchers conclude, could open a new front against a disease that has learned to survive nearly everything else thrown at it.

Subject of Research: Metabolic signalling by ASS1-derived argininosuccinate and NT5C2 in B cell acute lymphoblastic leukaemia

Article Title: Argininosuccinate signalling drives carbon replenishment in B cell acute lymphoblastic leukaemia

Article References: Argininosuccinate signalling drives carbon replenishment in B cell acute lymphoblastic leukaemia. (2026). Nature Metabolism. https://doi.org/10.1038/s42255-026-01593-x

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01593-x

Keywords: B cell acute lymphoblastic leukaemia, ASS1, argininosuccinate, NT5C2, purine nucleoside biosynthesis, cancer metabolism, urea cycle, tyrosine kinase, BCR-ABL, metabolic reprogramming, therapeutic targets, Nature Metabolism